AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL

NEUTRAL Impact: 2/10 6-K
Horizon immediate Filed May 28, 2026 Processed 13d 6h ago SEC 0001213900-26-061791
Notable filing: 6-K
Latest settled — T+5d
AAPG ▼ -10.11% at T+5d
NEUTRAL call ✗ call lost -10.11% · α vs SPY -10.06% · entry $19.88 → $17.87
Next anchor: T+20d in 16d
Currently $17.07 · -14.13% from $19.88 entry
Entry anchored
May 27, 12:20 PM ET
via Databento tick
T+1d
+0.65%
call +0.65% · α +0.41%
$20.01
settled 12d ago
T+5d
-10.11%
call -10.11% · α -10.06%
$17.87
settled 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Ascentage Pharma issued a voluntary announcement that its RSU trustee purchased 100,000 existing shares on-market for HK$3,977,000 (approximately HK$39.77/share) to satisfy RSU vesting obligations under the 2022 RSU Scheme. This is a routine trust administration action — the trustee buys shares to deliver against previously granted awards, not an open-market buyback by the company. The purchase represents ~0.027% of outstanding shares, immaterial in size. The filing is purely administrative and has no effect on the company's fundamentals or outlook.

Actionable Insight

No trading action warranted. This is a routine trustee RSU share purchase with zero materiality. The 20-F cross-filing context provides the annual report reference but this 6-K adds no new operational information. Monitor upcoming quarterly disclosures for pipeline updates.

Key Facts

  • Trustee purchased 100,000 existing shares on May 27, 2026 at ~HK$39.77 per share for total consideration of HK$3,977,000
  • Purchased shares represent ~0.0268% of total issued shares
  • Shares are held by trustee under 2022 RSU Scheme to satisfy vesting obligations, not a company buyback
  • Trustee now holds 2,265,000 shares total; trustee does not exercise voting rights
  • No new RSU grants were made — this is a routine delivery transaction for prior awards

Financial Impact

HK$3,977,000 (~0.027% of outstanding shares) — immaterial

dilution

Risk Factors

  • No material risks from this filing — administrative only

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-061791
Document: ea029232601ex99-1.htm0001213900-26-061791
Document: 0001213900-26-061791-index-headers.html0001213900-26-061791
Document: 0001213900-26-061791-index.html0001213900-26-061791
Document: 0001213900-26-061791.txt0001213900-26-061791
16 reports for AAPG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AAPG — sortable, filterable
Type Now
Jun 1, 2026
9d ago
6-K
NEUTRAL ★ 4/10
$19.08 $17.20▼ −9.85%▼ −7.10%$17.07 (−10.53%)
May 28, 2026
12d ago
6-K
NEUTRAL ★ 2/10
$20.01 $17.20▼ −14.04%▼ −11.52%$17.07 (−14.69%)
May 28, 2026
13d ago
6-K
NEUTRAL ★ 2/10
$19.88 $17.87▼ −10.11%▼ −10.06%$17.07 (−14.13%)
May 22, 2026
19d ago
6-K
NEUTRAL ★ 5/10
$21.01 $19.08▼ −9.19%▼ −10.86%$17.07 (−18.75%)
May 22, 2026
19d ago
Press Release
NEUTRAL ★ 4/10
$21.01 $19.08▼ −9.19%▼ −10.84%$17.07 (−18.75%)
May 13, 2026
28d ago
6-K
NEUTRAL ★ 3/10
$21.38 $18.99▼ −11.18%▼ −10.02%$17.07 (−20.16%)
May 12, 2026
29d ago
6-K
NEUTRAL ★ 2/10
$21.16 $18.56▼ −12.29%▼ −12.37%$17.07 (−19.33%)
Apr 22, 2026
7w ago
6-K
BULLISH ★ 7/10
$25.13 $22.75▼ −9.47%▼ −9.53%$17.07 (−32.07%)
Apr 22, 2026
7w ago
Press Release
BULLISH ★ 7/10
$25.13 $22.75▼ −9.47%▼ −9.53%$17.07 (−32.07%)
Apr 20, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$26.36 $23.37▼ −11.34%▼ −12.26%$17.07 (−35.24%)
Showing 10 of 16

US Market Status

Market Open — Closes in 1h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access